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Circulating haemopoietic and endothelial
progenitor cells are decreased in COPD
P. Palange*, U. Testa#, A. Huertas*, L. Calabro`#, R. Antonucci*, E. Petrucci#,
E. Pelosi#, L. Pasquini#, A. Satta", G. Morici+,e, M.A. Vignola1,e,{ and
M.R. Bonsignore1,e
ABSTRACT: Circulating CD34+ cells are haemopoietic progenitors that may play a role in tissue
repair. No data are available on circulating progenitors in chronic obstructive pulmonary disease
(COPD).
Circulating CD34+ cells were studied in 18 patients with moderate-to-severe COPD (age:
mean¡SD 68¡8 yrs; forced expiratory volume in one second: 48¡12% predicted) and 12
controls, at rest and after endurance exercise. Plasma concentrations of haematopoietic growth
factors (FMS-like tyrosine kinase 3 (Flt3) ligand, kit ligand), markers of hypoxia (vascular
endothelial growth factor (VEGF)) and stimulators of angiogenesis (VEGF, hepatocyte growth
factor (HGF)) and markers of systemic inflammation (tumour necrosis factor (TNF)-a, interleukin
(IL)-6, IL-8) were measured.
Compared with the controls, the COPD patients showed a three-fold reduction in CD34+ cell
counts (3.3¡2.5 versus 10.3¡4.2 cells?mL-1), and a 50% decrease in AC133+ cells. In the COPD
patients, progenitor-derived haemopoietic and endothelial cell colonies were reduced by 30–50%.
However, four COPD patients showed progenitor counts in the normal range associated with
lower TNF-a levels. In the entire sample, CD34+ cell counts correlated with exercise capacity and
severity of airflow obstruction. After endurance exercise, progenitor counts were unchanged,
while plasma Flt3 ligand and VEGF only increased in the COPD patients. Plasma HGF levels were
higher in the COPD patients compared with the controls and correlated inversely with the number
of progenitor-derived colonies.
In conclusion, circulating CD34+ cells and endothelial progenitors were decreased in chronic
obstructive pulmonary disease patients and could be correlated with disease severity.
KEYWORDS: CD34+ cells, chronic obstructive pulmonary disease, exercise, growth factors,
hypoxia
T
he systemic effects of chronic obstructive
pulmonary disease (COPD) have been
studied with regards to inflammation,
chronic oxidative stress and skeletal muscle
dysfunction [1]. Despite evidence of neutrophils
activation in peripheral blood of COPD patients
[2], inflammatory infiltration of the airways in
severe disease [3], and smoking-induced increase
in granulocyte turnover, little is known about the
effects of COPD at the level of bone marrow [4].
Data on the erythrocyte lineage have shown that
anaemia occurs in 13% of COPD patients and is
associated with increased inflammatory markers
[5], and may predict poor survival [6]. Data on
other blood lineages are scarce due to the need of
invasive techniques to obtain bone marrow
samples.
This difficulty can be partly overcome by studying
circulating bone marrow-derived progenitors.
These cells are positive for CD34 and other
markers (CD38, human leukocyte antigen (HLA)-
DR) acquired during differentiation [7], and
yield indirect information on haemopoiesis.
Circulating CD34+ cells are also believed to be
involved in tissue repair. Bone marrow-derived
progenitors can engraft in several organs
including the lungs [8, 9] and skeletal muscle
[10]. The latter finding is of interest in COPD,
given the frequent occurrence of skeletal muscle
dysfunction associated with increased muscle
apoptosis [11], fibrosis [12] and inflammatory
activation [13].
At least part of the repair potential of CD34+ cells
may depend on the AC133+ endothelial progeni-
tor cell (EPC) subpopulation [14]. EPCs have
been used to treat patients with myocardial [15]
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and vascular [16] disease. Low circulating EPC counts were
found in patients with cardiovascular risk factors [17], and
bone marrow CD34+ cells showed a low proliferative capacity
in patients with chronic ischemic heart disease [18]. However,
exercise training increased EPCs [19]. Whether COPD affects
circulating EPCs and/or CD34+ cell proliferative capabilities is
unknown.
Exercise might be a useful model to study circulating pro-
genitors. Long-distance runners showed increased circulating
TABLE 1 Anthropometric characteristics and pulmonary
function data of chronic obstructive pulmonary
disease (COPD) patients and control subjects
COPD patients Control subjects
Subjects n 18 12
Age yrs 68¡8 63¡7
BMI kg?m-2 26.8¡4.2 25.9¡2.1
FEV1 L 1.4¡0.3* 3.3¡0.5
FEV1 % pred 48¡12* 106¡15
FVC L 2.7¡0.4* 4.1¡0.6
FVC % pred 73¡16* 102¡15
FEV1/FVC % 51¡10* 81¡9
Pa,O2 mmHg 76¡9* 93¡3
Pa,CO2 mmHg 41¡4 39¡3
pH 7.41¡0.05 7.42¡0.02
Sa,O2 % 93¡4* 98¡1
Data are presented as mean¡SD. BMI: body mass index; FEV1: forced
expiratory volume in one second; % pred: percentage predicted; FVC: forced
vital capacity; Pa,O2: arterial oxygen tension; Pa,CO2: arterial carbon dioxide
tension; Sa,O2: arterial oxygen saturation. *: significant differences (p,0.05)
between groups. 1 mmHg50.133kPa.
TABLE 2 Exercise data# in chronic obstructive pulmonary
disease (COPD) patients and control subjects
COPD patients Control subjects
Load W 92¡15* 133¡18
V9O2 peak L?min
-1 1.53¡0.24* 2.22¡0.25
V9O2 peak mL?kg
-1?min-1 19.8¡2.6* 28.5¡4.0
V9E peak L?min-1 48.7¡14.6* 62.5¡5.6
TV L 1.6¡0.3* 2.3¡0.3
Rf 31.4¡7.2 28.9¡6.1
tI /ttot 0.40¡0.01* 0.50¡0.01
RER 1.00¡0.1 1.02¡0.05
V9E/V9CO2 29.3¡5.4 25.4¡1.7
HR 125.8¡11.1* 138.6¡15.4
V9O2-LT L?min
-1 1.07¡0.23* 1.45¡0.25
V9O2-LT/V9O2 peak 0.55¡0.13* 0.66¡0.11
Data are presented as mean¡SD. W: Watt; V9O2: oxygen uptake; V9E: minute
ventilation; TV: tidal volume; Rf: respiratory frequency, breaths per minute; tI /
ttot: inspiratory time/total respiratory time; RER: respiratory exchange ratio;
V9CO2: carbon dioxide output; HR: heart rate, beats per minute; LT: lactic
threshold. #: maximal incremental test. *: significant difference (p,0.05)
between groups.
TABLE 3 Blood cell counts in control subjects and in
chronic obstructive disease (COPD) patients at
baseline (BL) and after endurance exercise (Exe)
COPD patients Control subjects
BL Exe BL Exe
RBC 106?mL-1 5.00¡0.51 5.07¡0.57 4.87¡0.35 4.93¡0.40
Hb g?dL-1 14.7¡1.3 15.1¡1.1 14.9¡1.0 15.0¡1.1
WBC 103?mL-1 6.96¡1.31 7.73¡1.64 6.14¡1.27 6.62¡1.67
Neutrophils % 64.8¡6.1* 63.0¡7.3 57.0¡6.9 58.6¡7.3
Lymphocytes % 23.2¡5.7* 25.5¡6.7 31.6¡7.4 29.7¡8.1
Monocytes % 6.5¡1.4 5.9¡0.8 6.2¡1.0 6.0¡1.1
Eosinophils % 2.8¡1.6 2.7¡1.3 2.6¡1.3 2.4¡1.3
Basophils % 0.6¡0.3 0.7¡0.3 0.7¡0.2 0.7¡0.2
Platelets
105?mL-1
234¡73 253¡74 199¡45 216¡35
Data presented as mean¡SD. RBC: red blood cells: Hb: haemoglobin; WBC:
white blood cells. *: significant difference (p,0.05) between resting values in
COPD patients and controls (unpaired t-test).
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FIGURE 1. a) White blood cells (WBC) and b) CD34+ cells at baseline (BL) and
after endurance exercise (Exe) in chronic obstructive pulmonary disease (COPD)
patients ($) and in control subjects (#). Note the marked uniform reduction in
CD34+ cells in COPD patients compared with the control subjects. *: p,0.001,
COPD versus controls.
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CD34+ cells and exercise-induced release of factors/cytokines
active on the bone marrow (FMS-like tyrosine kinase 3 (Flt3)
ligand, interleukin (IL)-6, granulocyte colony-stimulating
factor (G-CSF), tumour necrosis factor (TNF)-a) [20, 21].
Mobilisation of endothelial progenitor cells also occurred after
exercise in middle-aged untrained subjects [22], but little is
known on the relationship between circulating progenitors and
exercise limitation in COPD, or on the effects of inflammatory
activation on progenitors.
Finally, COPD may affect haemopoietic and endothelial
progenitors through alterations in arterial blood gases or
inflammatory mediators. In vitro, very low arterial oxygen
tension preserved early haemopoietic progenitors [23], while
promoting their differentiation [24]. No study addressed the
effects of mild hypoxaemia on circulating CD34+ cells and
subpopulations in vivo in COPD patients.
The present study was designed to answer whether or not COPD
affects circulating progenitor cell numbers and frequency.
SUBJECTS AND METHODS
In total, 18 ex-smokers with COPD and 12 age-matched
nonsmokers (controls) were studied (table 1). Inclusion criteria
for patients were: 1) COPD of moderate severity (Global
Initiative for Chronic Obstructive Lung Disease stage 2); 2)
stable clinical conditions (i.e. no change in pulmonary function
tests or exacerbation in the 4 weeks preceding the study); and
3) mild, resting hypoxaemia (arterial oxygen tension: Pa,O2
.7.89 kPa). No patient was receiving systemic steroids at the
time of the study. Inclusion criteria for controls were: 1) age
o50 yrs; 2) a sedentary lifestyle; 3) normal spirometry and
arterial blood gases; 4) no other clinically evident disease; and
5) a wish to participate in the study. Patients with cardio-
vascular, cerebrovascular, neuromuscular, rheumatological
and/or metabolic disorders, as assessed by clinical and
standard laboratory findings tests, were excluded from the
studies. Patients were also excluded if they suffered from any
disease precluding execution of exercise tests.
The protocol was approved by the Ethical Committee of the
University of Rome (Italy), and all subjects gave their informed
consent.
Study protocol
Each subject visited the laboratory three times. At the first visit,
a complete clinical assessment and pulmonary function tests
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FIGURE 2. Representative flow cytometry analyses of CD34+ subpopulations in one control subject (a–d) and two chronic obstructive pulmonary disease patients (e–l),
at rest. Peripheral blood mononuclear cells have been labelled either with irrelevant mouse immunoglobulins conjugated with: phycoerythrin (PE); fluorescein isothiocyanate
(FITC) fluorochromes; PE-conjugated anti-CD34+ monoclonal antibodies (mAb) and FITC-conjugated anti-human lymphocyte antigen-DR; FITC-conjugated anti-CD45; or
FITC-conjugated anti-CD38 mAb.
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(Quark PFT; COSMED, Rome, Italy) were obtained. A sample
was drawn from the radial artery for arterial blood gas
determination at rest while breathing room air. At the second
visit each subject underwent an incremental exercise stress test
on the cycle ergometer (Ergoline 800, Bitz, Germany) to
determine peak oxygen uptake (V9O2peak) and lactic threshold.
Pulmonary gas exchange indexes were measured breath-by-
breath by a computerised system as previously described [25].
Oxygen uptake (V9O2; at standard temperature and pressure,
dry (STPD)), CO2 output (V9CO2; STPD), minute ventilation
(V9E; at body temperature and pressure, saturated with water
vapour) and respiratory frequency were measured. Heart rate
(HR) was derived from R–R intervals measured from a 12-lead
ECG. At the third visit, each subject performed a submaximal
exercise test on a cycle ergometer at a work-rate corresponding
to 70% of V9O2peak for 20 min (endurance test). Exercise
sessions were planned a minimum of 48 h apart. All tests
were obtained while the subjects breathed room air.
Venous blood samples (20 mL) were drawn before and
immediately after the endurance test for analysis of blood cell
counts and CD34+ cells. Total blood cell counts were
determined by standard haemocytometry. Peripheral blood
mononuclear cells (PBMCs) were obtained by standard Ficoll
gradient centrifugation. The cells were carefully washed with
PBS, resuspended in PBS containing 2 mg?mL-1 bovine serum
albumin and labelled for 30 min at 4uC with the following
antibodies: 1) anti-CD34 conjugated with phycoerythrin (PE);
2) anti-CD38; or 3) anti-HLA-DR, all labelled with fluoresceine
isothiocyanate (FITC; Becton Dickinson–Pharmingen, Lincoln
Park, NJ, USA). In some experiments PBMCs were labelled
with anti-CD34 (FITC-conjugated) and either anti-very late
activation antigen (VLA)-4 or anti-Flt3 (both PE-conjugated).
For a negative control, the cells were labelled with isotype-
matched mouse immunoglobulin labelled with either PE or
FITC. After two washings in cold PBS, the cells were analysed
for fluorescence in a fluorescence-activated cell sorter flow
cytometer (Becton-Dickinson). The level of positivity of entire
body was evaluated as ‘‘dim’’ or ‘‘bright’’ according to the
fluorescence labelling intensity. CD34+ cells and their sub-
populations were expressed as percentage of total PBMCs. In
some experiments PBMCs were labelled with PE-conjugated
anti-AC133 monoclonal antibodies (Miltenyi Biotech, Bergisch
Gladbach, Germany).
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FIGURE 3. Representative flow cytometry analyses of CD34+ subpopulations in one control subject (a–d) and two chronic obstructive pulmonary disease patients (e–l),
after endurance exercise. Peripheral blood mononuclear cells have been labelled either with irrelevant mouse immunoglobulins conjugated with: phycoerythrin (PE);
fluorescein isothiocyanate (FITC) fluorochromes; PE-conjugated anti-CD34+monoclonal antibodies (mAb) and FITC-conjugated anti-human lymphocyte antigen-DR; FITC-
conjugated anti-CD45; or FITC-conjugated anti-CD38 mAb.
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Flow cytometry analysis was carried out using software gating
on lymphocytes. At least 105 gated events were acquired for
each determination.
For the colony forming unit (CFU) assay, PBMCs were seeded
at 36105 cells?mL-1?dish-1 (Falcon 1008; Becton Dickinson) in
0.9% methylcellulose and 40% foetal calf serum (Gibco, Grand
Island, NY, USA) in Iscove’s modified Dulbecco’s medium
(Gibco), which was supplemented with 1.5 IU?mL-1 erythro-
poietin for erythrocyte burst-forming units (E-BFU) colonies
and 10 ng?mL-1 of both granulocyte-monocyte colony-
stimulating factor and G-CSF for granulocyte-monocyte CFU
(GM-CFU) colonies. Colonies were counted under an inverted
microscope after 14–16 days of culture.
For endothelial progenitor colony assay, PBMCs were resus-
pended in EndoCultTM liquid medium (Stem Cell Techno-
logies, Vancouver, BC, Canada) and plated (56106 cells) on
fibronectin-coated 6-well dishes. After 2 days of culture at
37uC, nonadherent cells were collected and 16106 cells?well-1
were plated in duplicate on fibronectin-coated 24-well dishes.
After 3–5 additional days of culture, endothelial cell CFUs (EC-
CFU) were counted under an inverted microscope.
Biochemical analyses
These assays were performed in 17 COPD patients and six
control subjects. Aliquots of serum were prepared and stored
at -80uC for determination by immunoassay (ELISA, R&D
Systems, Minneapolis, MN, USA) of the following. 1) Flt3
ligand and kit ligand (KL), both acting on early haemopoietic
stages (detection limit: 5.0 pg?mL-1 for both) [26]. 2) Vascular
endothelial growth factor (VEGF), as a marker of tissue
hypoxia and angiogenesis (detection limit: 5.0 pg?mL-1) [27].
3) Hepatocyte growth factor (HGF), a mediator known to
activate proliferation and migration of endothelial cells and
induce angiogenesis [28] (detection limit: 20 pg?mL-1). 4) TNF-
a (detection limit 0.2 pg?mL-1), and IL-8 (detection limit:
0.2 pg?mL-1) as markers of systemic inflammation. As well as
IL-6 (detection limit: 0.16 pg?mL-1), which is known to be
released during prolonged exercise [29]. The serum concentra-
tion of cortisol and muscle enzymes (lactic dehydrogenase,
creatine phosphokinase) as markers of muscle damage was
determined using standard methods.
Statistics
Data are expressed as means¡SD. ANOVA and t-test or
Wilcoxon test were used to compare experimental conditions.
Paired t-tests were used in each group to compare baseline and
post-exercise data. Unpaired t-tests were used to compare the
COPD and control groups. When data appeared to be
abnormally distributed, Wilcoxon or Mann-Whitney U-tests
were used for paired or unpaired comparisons, respectively.
Linear regression was used to assess relationships between
variables. The level of significance was set at p,0.05.
RESULTS
Subjects and functional data
Table 1 summarises anthropometric and pulmonary function
data and arterial blood gas measurements. COPD patients
showed moderate-to-severe functional deterioration. During
maximal exercise stress test (table 2) COPD patients attained
lower V9O2, V9E and HR at peak exercise than controls.
Endurance test
Mean¡SD workload was 133¡18 W in controls, and 92¡15 W
in COPD patients (p,0.001 by unpaired t-test). All normal
subjects and 17 COPD patients completed the 20-min exercise
test. One patient stopped at 10 min because of intolerable
dyspnoea.
Red blood cells and platelet counts were similar in the control
subjects and COPD patients, both pre- and post-exercise
(table 3). A slightly anaemic state (haemoglobin concentration
,13.5 mg?dL-1) was found in one COPD patient and one
control subject.
White blood cell (WBC) counts were in the normal range in
both groups. However, COPD patients showed slightly higher
WBC (fig. 1a) and neutrophil differential counts compared
with controls at baseline (table 3). The latter difference
between groups was not found in the post-exercise samples.
Circulating CD34+ cells, clonogenetic assays and
haemopoietic growth factors
Circulating CD34+ cells as the percentage of lymphocytes were
approximately three times lower in the COPD patients when
compared with the normal subjects at rest (0.22¡0.19 versus
0.57¡0.26%), and were unaffected by endurance exercise in
either group (COPD: 0.21¡0.16%; controls: 0.61¡0.28%).
These differences were of the same magnitude when CD34+
cells were expressed as absolute numbers per mL blood
volume, both at rest (3.3¡2.5 versus 10.3¡4.2; p,0.001) and
after endurance exercise (3.8¡3.1 versus 11.2¡5.4; p,0.001;
fig. 1b). In addition, double labelling experiments with anti-
CD34 and anti-CD38 or anti-HLA-DR monoclonal antibodies
have been performed to allow the identification of immature
(34+/38- and 34+/HLA-DR-) and mature (34+/38+ and 34+/
HLA-DR+) haemopoietic progenitors [7]. CD34+ cell sub-
populations (34+/38-, 34+/38+, 34+/HLA-D-, 34+/HLA-DR+)
were uniformly decreased in COPD patients compared with
TABLE 4 CD34+ subpopulations# in control subjects and
in chronic obstructive pulmonary disease
patients (COPD) at baseline (BL) and after
endurance exercise (Exe)
COPD Patients Normal Subjects
BL Exe BL Exe
CD34+ CD38- 0.37¡0.63 0.57¡0.07 1.77¡0.93 2.10¡0.60
CD34+ CD38+ 3.12¡2.82 3.90¡ 3.07 8.72¡3.90 9.49¡4.21
CD34+ HLA-DR- 3.14¡3.08 4.20¡3.50 8.85¡4.18 10.10¡5.10
CD34+ HLA-DR+ 0.36¡0.20 0.40¡0.26 1.50¡1.10 1.93¡0.96
CD34+ VLA-4- 0.15¡0.14 0.31¡0.24 0.36¡0.31 0.31¡0.35
CD34+ VLA-4+ 3.35¡2.60 4.21¡3.06 10.10¡8.40 11.70¡6.40
CD34+ CXCR4- 2.06¡1.92 2.79¡1.36 7.15¡3.70 7.90¡5.10
CD34+ CXCR4+ 1.43¡1.10 1.71¡1.44 3.46¡3.55 4.10¡2.20
Data are presented as mean¡SD. HLA-DR: human leukocyte antigen-DR; VLA-4:
very late activation antigen-4; CXCR: C-X-C motif chemokine receptor 4. Analysis
by ANOVA showed a significant difference between COPD and control groups for
all subpopulation (p,0.005 for all comparisons), but no difference between
baseline and post-exercise data. #: expressed as number per mL of blood.
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the controls (figs 2, 3; table 4). The endurance exercise did not
change the number of circulating CD34+ cells (fig. 4; table 4).
In some COPD patients (n54, 22% of the sample) CD34+ cell
counts were in the normal range (0.56¡0.14% of lymphocytes)
as opposed to the mean value of 0.12¡0.03% in the rest of the
COPD group (n514). The patients with normal CD34+ cell
counts could not be identified based on anthropometric
characteristics or COPD severity. They only showed a trend
towards a higher V9O2peak (21.5¡3.1 versus 18.9¡2.1 mL?
kg-1?min-1; p50.07) and lower plasma TNF-a levels (rest:
1.78¡0.79 versus 2.30¡1.22 pg?mL-1; post-exercise: 1.11¡0.11
versus 1.96¡0.77 pg?mL-1, p,0.05).
Given the decrease in the number of circulating CD34+ cells in
COPD patients, the current authors evaluated whether the
number of circulating haemopoietic progenitor cells, as
measured by standard clonogenetic assays, were correspond-
ingly decreased. COPD patients displayed a significantly
reduced number of CFUs compared with the controls (fig. 4a
and 4c). In both groups, E-BFU and GM-CFU numbers, after
endurance exercise, were similar to those observed at rest
(fig. 4a and 4c). It is of interest to note that the majority of
COPD patients displayed not only a reduced colony number,
but also smaller E-BFU and GM-CFU compared with the
controls (fig. 5). In figure 5 the representative pictures of
individual E-BFU and GM-CFU colonies derived from the
blood of a control subject (fig. 5c), a COPD patient with a
normal CD34+ cell count (fig. 5b) and a COPD patient with a
low CD34+ cell count (fig. 5a) are shown. The size of individual
E-BFU colonies (each included in a separate box) and of GM-
CFU colonies are smaller in COPD patients with low CD34+
cell counts (fig. 5a, observe the three individual E-BFUs and
the two GM-CFU colonies), compared with those observed for
E-BFU and GM-CFU colonies derived from normal controls
(fig. 5c) or COPD patients with normal CD34+ cell count
(fig. 5b).
Given the reduced number of circulating haemopoietic
progenitors in COPD, the current authors evaluated the
plasma concentration of several cytokines normally involved
in the survival and proliferation of haemopoietic progenitors.
In this context, the current authors’ focused on the Flt3 ligand
and KL. Flt3 ligand expression on CD34+ cell surface did not
differ between COPD patients and controls (data not shown).
Plasma Flt3 ligand concentration was similar in COPD patients
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FIGURE 4. a) Erythrocyte burst forming units E-BFU; b) plasma Flt3 ligand; c) granulocyte-monocyte colony-forming units (GM-CFU); and d) plasma kit ligand, at
baseline (BL) and after endurance exercise (Exe) in chronic obstructive pulmonary disease (COPD) patients (&) and in control subjects (h). Note the marked reduction in E-
BFU and GM-CFU in COPD patients at BL and after Exe compared with normal subjects. *: p,0.05 COPD versus controls; #: p,0.05 Exe versus BL.
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and controls at baseline; it increased significantly after
endurance exercise in COPD patients only (fig. 4b). Plasma
KL levels, did not differ between groups or experimental
conditions (fig. 4d).
In the entire group of subjects studied (i.e. COPD patients and
controls) circulating CD34+ cell counts correlated directly with
V9O2peak (fig 6d; r
250.37, p,0.05), resting Pa,O2 (6a; r
250.30,
p,0.05) and with the severity of airway obstruction assessed
as forced expiratory volume in one second (FEV1)/forced vital
capacity (6c; r250.39; p,0.05). No correlation was found
between CD34+ cell counts and carbon dioxide arterial tension
(fig. 6b). The r2 values were calculated for the entire group of
subjects studied (i.e. COPD patients and controls combined).
Circulating AC133+ cells, endothelial cell progenitors and
angiogenetic growth factors
Circulating AC133+ cells, in COPD patients at rest, were
approximately half the value found in control subjects and
were unaffected by endurance exercise in either group (fig. 7a).
The decrease in AC133+ cells was also evident when expressed
as absolute cell count per mL of blood volume both at
rest (COPD: 2.5¡1.7 cells?mL-1; control: 6.1¡3.0) and after
endurance exercise (COPD: 2.7¡1.8 cells?mL-1; control: 6.5¡3.1
cells?mL-1). Weak but significant direct relationships were
found in the entire group between baseline AC133+ cell counts
and Pa,O2 (r
250.21, p,0.05), FEV1 (r250.19, p,0.05) and the
fitness level expressed as maximal load in W (r250.236,
p,0.05).
A consistent decrease in the number of circulating endothelial
progenitors per mL of blood in COPD patients was also found.
A specific clonogenic assay showed that their number was
significantly decreased in COPD patients at rest (COPD
patients: 18.2¡7.2 EC-CFU ?mL-1 of blood; control subjects:
30¡4 EC-CFU ?mL-1 of blood) and after exercise (COPD
patients: 20.1¡8.4 CFU-EC?mL-1 of blood; control subjects:
32.2¡8.2 EC-CFU ?mL-1 of blood; fig. 7c).
As for changes in plasma concentration of endothelial growth
factors, VEGF and HGF showed some marked and interesting
differences (fig. 7b and d). Plasma VEGF concentration was
higher in COPD patients than in control subjects at rest (COPD
patients: 69¡68 pg?mL-1; control subjects: 26¡8 pg?mL-1),
and increased further after exercise (COPD patients:
201¡205 pg?mL-1; control subjects: 27¡2 pg?mL-1). Plasma
HGF levels at rest were higher in COPD patients when
compared with the control subjects, but remained unchanged in
either group after exercise (fig. 7d). HGF, but not VEGF, levels
correlated inversely with the results of clonogenetic tests (fig. 8).
Other biochemical measurements
Muscle enzymes (lactate dehydrogenase and creative kinase)
and cortisol levels were similar in COPD patients and control
subjects and remained unchanged in post-exercise samples
(table 5). Plasma TNF-a concentration did not differ signifi-
cantly between COPD and control groups, even though some
differences were found between COPD patients with normal
and low CD34+ cell counts as reported previously in the results
section.
Plasma IL-6 levels were increased in COPD patients compared
with controls (p,0.01 by ANOVA; table 5). IL-8 values did not
differ significantly between groups but showed a large
dispersion, with some COPD patients showing very high
plasma concentrations at rest.
DISCUSSION
In COPD patients with moderate-to-severe respiratory impair-
ment, blood cell counts were normal while circulating
haemopoietic and endothelial progenitor counts were greatly
decreased, when compared with control subjects. The number
of progenitor-derived colonies was correspondingly low
(-30– -50%) in the COPD group. However, ,20% of COPD
patients, clinically and functionally similar to the rest of the
group, showed normal progenitor counts associated with less
inflammatory activity as estimated by plasma TNF-a concen-
trations. Endurance exercise did not affect circulating CD34+
cells in either COPD patients or control subjects. The post-
exercise increase in plasma VEGF suggested activation of the
hypoxic pathway in COPD patients, but not in the control
subjects. The endurance exercise in COPD patients appears to
make the initial hypoxic condition, observed at rest, more
severe and, therefore, stimulates VEGF release. In the entire
sample, circulating progenitor counts correlated directly with

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FIGURE 5. Representative pictures of single colonies of erythrocyte burst
forming units (E-BFU) and granulocyte-monocyte colony-forming units (GM-CFU)
obtained in clonogenetic culture from the following. a) A chronic obstructive
pulmonary disease (COPD) patient with a low CD34+ cell count. b) A COPD patient
with a normal CD34+ cell count. c) A control subject. For E-BFU each box
represents an individual E-BFU colony, therefore, the E-BFU colonies from the
COPD patient with low CD34+ cells (a) are markedly smaller than those observed in
controls (c) or in a COPD patient with normal CD34+ cell count (b).
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V9O2peak and indices of COPD severity such as FEV1 and Pa,O2
tension. Overall, the current data indicates that the bone
marrow is an important, previously unrecognised, systemic
target in the pathophysiology of COPD.
To the best of the authors’ knowledge, this study is the first to
report that circulating progenitors are decreased in moderate-
to-severe COPD. However, the current data only allow the
indirect estimation of haemopoietic function, and detailed
investigations on possible mechanism(s) will require invasive
bone marrow sampling. Despite this limitation, the current
results do provide some information. Normal peripheral blood
cell counts in COPD patients do not support decreased cell
production and/or release, as a likely explanation for the
current authors findings, at least where the haemopoietic
compartment is concerned. WBC counts were higher in COPD
patients than control subjects and platelet counts were in the
normal range. Only one subject in each group showed slightly
reduced haemoglobin concentration, confirming the low
prevalence of anaemia in COPD [5], whereas 80% of the
COPD patients showed greatly reduced CD34+ cells compared
with the control subjects.
Low circulating progenitor counts may be secondary to defects
in cell mobilisation mechanisms. The current authors tested
this hypothesis, but found normal expression of adhesion
molecules implicated in progenitor homing and migration
(very late activation antigen-4 (VLA-4), chemokine (CC motif)
receptor 5 (CCR5), C-X-C motif chemokine receptor 4
(CXCR4)) on CD34+ cells, lymphocytes and monocytes of
COPD patients (unpublished observations: Testa U., Istituto
Superiore di Sanita’, Rome, Italy). The data in COPD patients,
herefore, mimicked the low proliferation of CD34+ cells recently
found in patients with chronic ischemic heart disease [18],
which occurred in the absence of obvious mobilisation defects.
The present authors also tested whether insufficient haemo-
poietic stimulation may occur in COPD patients. Plasma Flt3
ligand and KL concentrations, both being important haemo-
poietic growth factors [26], were similar in COPD patients and
controls. Furthermore, Flt3 ligand concentrations increased
after exercise in COPD patients, similar to data obtained in
athletes after intense exercise [20, 21]. No difference was found
in Flt3 ligand expression on CD34+ cells or monocytes between
COPD and controls (data not shown), discounting the
possibility that the increase in Flt3 ligand could be secondary
to a lack of receptors in COPD patients. Altogether, insufficient
bone marrow stimulation in COPD is not supported by the
current results.
Inflammatory mediators could be involved in the pathogenesis
of low circulating precursor counts in COPD. The evidence in
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FIGURE 6. Correlations between CD34+ versus: a) arterial oxygen tension (Pa,O2; r250.30, p,0.05); b) carbon dioxide arterial tension (Pa,CO2); c) forced expiratory
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subjects. 1 mmHg50.133 kPa.
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favour of this hypothesis is that COPD patients with CD34+
cells in the normal range tended to show lower TNF-a values.
In addition, IL-6 and IL-8 concentrations were, on average,
higher in COPD patients than in the control subjects. No clear
relationship was found between inflammatory marker con-
centrations and circulating progenitors. Therefore, more data
are necessary to confirm the role of inflammation in modulat-
ing CD34+ cells in COPD.
Circulating EPCs were also assessed in the current study, with
a special regard to exercise, since it is a known physiological
stimulus for their release [22]. Similar to haemopoietic cells,
EPCs decreased in COPD patients and showed decreased
proliferation when compared with the control subjects. A
decreased number of EPCs was also observed in other
pathological conditions, including coronary artery diseases
[17], chronic ischemic heart disease [18], congestive heart
failure [30], rheumatoid arthritis [31] and haemodialysis
patients [32], all these conditions are associated with an
increased cardiovascular risk. It was suggested in these
pathological conditions that the decreased number of
circulating EPCs might be related to impaired neovascularisa-
tion and could contribute to the increased cardiovascular risk
observed in these conditions. Importantly, a recent study by
WERNER et al. [33] provided clear evidence that the level of
circulating EPCs predicts the occurrence of cardiovascular
events and death from cardiovascular causes and helps to
identify patients who are at an increased cardiovascular risk.
The same could apply for COPD patients. In congestive heart
failure [30] and rheumatoid arthritis [31], it was proposed as
playing an inhibitory role for TNF-a. The biochemical
mechanisms responsible for the decreased EPC number in
COPD patients remains to be determined.
Exercise did not increase EPCs in either group, possibly
because of insufficient intensity and/or duration of the test.
However, the pattern of release of pro-angiogenetic factors
differed greatly between COPD patients and controls. COPD
patients showed two-fold increase in VEGF and HGF levels
compared with the control subjects at rest, but only VEGF
increased further after exercise. HGF, but not VEGF, concen-
trations correlated inversely with the results of the clonogenic
tests. Both VEGF [27] and HGF [28] are pro-angiogenetic
factors, but their action profiles are different. VEGF is a marker
of activation of the hypoxic pathway [34], and its increase in
COPD patients suggests the occurrence of tissue hypoxia,
especially post-exercise.
HGF is a growth factor for hepatocytes, melanocytes, kerati-
nocytes and endothelial cells [35], and is a pulmotrophic factor
for the regeneration of an injured lung [36, 37]. Through its
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FIGURE 7. a) AC133+ cells, b) plasma vascular endothelial growth factor (VEGF), c) endothelial cell colony-forming units (EC-CFU, reported as colony number per mL of
blood) and d) plasma hepatocyte growth factor (HGF), at baseline (BL) and after endurance exercise (Exe), in chronic obstructive pulmonary disease (COPD) patients (&)
and in control subjects (h). Note the marked reduction in AC133+ and EC-CFU cells in COPD patients versus control subjects, and the increase in plasma HGF in COPD
patients at BL and at Exe compared with normal subjects. In addition note the increase in plasma VEGF levels in COPD patients at Exe compared with COPD at BL. *:
p,0.05, COPD versus controls; #: p,0.05, Exe versus BL.
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c-met receptor, HGF exerts multiple biological activities, such
as stimulation of epithelial alveolar proliferation and mobility
[38], and the induction of branching tubule formation. In the
lung, alveolar macrophages, endothelial cells [39], bronchial
cells [40] and fibroblasts [38] produce HGF. Due to the
increased secretion in an injured lung, HGF is presumed to
have an important role in the wound healing of pulmonary
epithelium [41]. Thus, plasma HGF levels have been found
to increase in vascular occlusion [42], COPD [43], lung
inflammatory diseases [44] and idiopathic lung fibrosis [43].
In addition to the effect of HGF on alveolar epithelium, HGF
stimulates the recruitment of EPCs in the injured lung and
stimulates the proliferation of bone marrow derived and
resident endothelial cells [45]. The stimulatory effect of HGF on
endothelial proliferation is greatly potentiated when it acts in
combination with VEGF [46].
In addition to the increase in angiogenetic mediators,
progenitor counts showed a relationship with the severity of
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FIGURE 8. Correlation between plasma hepatocyte growth factor (HGF; a, c, e) and vascular endothelial growth factor (VEGF; b, d, f) versus a) erythrocyte burst forming
units (E-BFU: r250.55, p,0.0001); b) E-BFU (r250.10, p50.06, not significant); c) granulocyte-monocyte colony-forming units (GM-CFU: r250.64, p,0.0001); d) GM-CFU
(r250.10, p50.06, not significant); e) endothelial cell colony-forming units (EC-CFU: r250.46, p,0.0005); and f) EC-CFU (r250.09, not significant). #: chronic obstructive
pulmonary disease (COPD) patients at baseline; $: control subjects at baseline; n: COPD patients after exercise; m: control subjects after exercise. The r2 values are for the
entire group of subjects studied (i.e. COPD patients and control subjects combined).
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hypoxaemia. The effects of low oxygen tensions on progenitors
in vivo are poorly defined, but the human bone marrow is
known to be a relatively hypoxic environment under physio-
logical conditions [47]. In addition, hypoxic gradients may be
important in regulating progenitor trafficking [48]. Exposure to
hypoxia in vitro increased the maturation rate of CD34+ cells,
while maintaining early precursors in a quiescent state [23, 24].
The current authors did not observe preferential release of less
immature precursors in more hypoxaemic COPD patients;
rather, all CD34+ subpopulations tested were uniformly
decreased (table 4).
Depression in the number and function of circulating
progenitors also correlated with the severity of airway
obstruction and the degree of physical fitness, suggesting that
depletion of CD34+ cells may be proportional to COPD
severity. A large number of patients with COPD at different
stages need to be studied to confirm this hypothesis.
Finally, CD34+ cells may be low in COPD patients due to an
increase in peripheric utilisation. The current authors hypothe-
sise that a high turnover of precursors may occur in COPD,
possibly related to tissue repair. Skeletal muscle may be a
potential target tissue for progenitors for the following reasons.
1) CD34+ cells can migrate into muscle connective tissue and
satellite cell niches [49]. 2) Exercising mice showed a higher
percentage of bone marrow-derived muscle cells compared
with sedentary mice [10], indicating precursor engraftment in
response to muscle injury. In the current authors’ previous
study, decreased CD34+ cell counts were found a few hours
after a marathon race, suggesting peripheral utilisation of
precursors [20]. Alternatively, decreased EPCs in COPD
patients may blunt the increase in muscle perfusion evoked
by hypoxia [27]. Unfortunately, muscle biopsies were not
obtained in the present study and association between low-
progenitor counts and muscle damage remains speculative.
The major limitation of the present study is that the group of
subjects studied was small and far from representative of the
entire clinical spectrum of COPD. Nevertheless, the difference
in CD34+ cells between COPD patients and age-matched
controls was large, indicating a likely relevant effect of the
disease on circulating precursors.
In conclusion, circulating CD34+ cells and endothelial
progenitor counts were decreased in most patients with
moderate-to-severe chronic obstructive pulmonary disease
and correlated with hypoxaemia, severity of airway obstruc-
tion, and peak oxygen consumption. The current data suggests
a possible link between systemic inflammation and a decrease
in circulating progenitors, as suggested in other pathological
conditions. The current authors conclude that bone marrow
should be considered as a previously unrecognised systemic
target of chronic obstructive pulmonary disease.
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